NEW YORK, Dec. 22, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces the commencement of an investigation into MiMedx Group, Inc. (“MiMedx”). If you are a MiMedx shareholder, you are encouraged to contact Scott+Scott at (800) 404-7770 or email [email protected] to discuss your legal rights.
MiMedx develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues, and human skin and bone.
On December 15, 2016, a complaint was filed in the District of Minnesota (the “Whistleblower Complaint”) that alleges that since at least 2014, MiMedx has engaged in a scheme of “channel stuffing,” which MiMedx used to fraudulently recognize revenue in its certified financial statements before the revenue had been realized or realizable and earned.
If you are a MiMedx shareholder and you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Michael Burnett at (800) 404-7770, or at [email protected].
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott have significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide.
CONTACT: Michael Burnett Scott+Scott, Attorneys at Law, LLP (800) 404-7770 [email protected]


SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 



